Antifibrotic activities of pirfenidone in animal models

European Respiratory Review

Volumn 20, Issue 120, 2011, Pages 85-97

  Schaefer, C J ^a   Ruhrmund, D W ^a   Pan, L ^a   Seiwert, S D ^a   Kossen, K ^a  

^a InterMune Inc   (United States)

Author keywords

Animal model; Antifibrotic; Fibrosis; Idiopathic pulmonary fibrosis; Pirfenidone

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BLEOMYCIN; HYDROXYPROLINE; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; OVALBUMIN; PIRFENIDONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; HEART ATRIUM FIBRILLATION; HEART MUSCLE FIBROSIS; HUMAN; KIDNEY FIBROSIS; LIVER DISEASE; LIVER FIBROSIS; LUNG EDEMA; LUNG FIBROSIS; LUNG TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OCULAR ALBINISM; OXIDATIVE STRESS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME; VITAL CAPACITY;

ADMINISTRATION, ORAL; ANIMALS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; HUMANS; KIDNEY DISEASES; LIVER CIRRHOSIS; PULMONARY FIBROSIS; PYRIDONES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 79958297487     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00001111     Document Type: Review

References (93)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
2. Lee KW, Everett TH, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006; 114: 1703-1712.
3. Nguyen DT, Ding C, Wilson E, et al. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm 2010; 7: 1438-1445.
4. Cho ME, Kopp JB. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs 2010; 19: 275-283.
5. Kelley CJ, Neilson EG. Tubulointerstitial diseases. In: Brenner BM, ed. The Kidney. 5th Edn. Philadelphia, WB Saunders and Company, 1996; pp. 1655-1679.
6. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
7. Gadekar SM. N-Substituted Pyridone and General Method for Preparing Pyridones. United States patent, number 3,839,346 (patent); 1974.
8. Lasky J. Pirfenidone. IDrugs 2004; 7: 166-172.
9. Margolin SB. Composition for Raparation and Prevention of Fibrotic Lesions. United States patent, number 5,716,632 (patent); 1990.
10. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-816.
11. Noble PW, Homer RJ. Idiopathic pulmonary fibrosis, new insights into pathogenesis. Clin Chest Med 2004; 25: 749-758.
12. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010; 9: 129-140.
13. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009; 136: 1364-1370.
14. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151.
15. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504.
16. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3: 364-372.
17. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99: 6292-6297.
18. Boon K, Bailey NW, Yang J, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One 2009; 4: e5134.
19. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007; 2: e482.
20. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006; 173: 188-198.
21. Yang IV, Burch LH, Steele MP, et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med 2007; 175: 45-54.
22. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069.
23. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
24. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2009; 35: 821-829.
25. Noble P, Albera C, Bradford W, et al. The CAPACITY (CAP) trials: randomized, double-blind, placebo-controlled, phase III trials of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2009; 179: A1129.
26. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; 9: CD003134.
27. Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002; 76: 234-242.
28. Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 906-913.
29. Sharma K, Kopp J, Fervenza F, et al. Improvement of renal function with pirfenidone in patients with diabetic nephropathy. NDT Plus 2009; 2: Suppl. 2, ii1514.
30. Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006; 55: 1663-1665.
31. Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009; 22: 279-285.
32. Bruss ML, Margolin SB, Giri SN. Pharmacokinetics of orally administered pirfenidone in male and female beagles. J Vet Pharmacol Ther 2004; 27: 361-367.
33. Mirkovic S, Seymour AM, Fenning A, et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 2002; 135: 961-968.
34. Giri SN, Wang Q, Xie Y, et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 2002; 23: 203-211.
35. Azuma A. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Respir Med 2010; 4: 301-310.
36. Moeller A, Ask K, Warburton D, et al. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008; 40: 362-382.
37. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005; 33: 9-13.
38. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008; 590: 400-408.
39. Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004; 24: 57-65.
40. Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995; 125: 779-785.
41. Iyer SN, Margolin S, Hyde DM, et al. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res 1998; 24: 119-132.
42. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 289: 211-218.
43. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol Lung Cell Mol Physiol 1999; 276: L311-L318.
44. Schelegle ES, Mansoor JK, Giri S. Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc Soc Exp Biol Med 1997; 216: 392-397.
45. Liu H, Drew P, Gaugler AC, et al. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant 2005; 5: 1256-1263.
46. Zhou H, Latham CW, Zander DS, et al. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J Heart Lung Transplant 2005; 24: 1577-1585.
47. Hirano A, Kanehiro A, Ono K, et al. Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am J Respir Cell Mol Biol 2006; 35: 366-377.
48. Shimizu T, Kuroda T, Hata S, et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998; 54: 99-109.
49. Takakura K, Fujimori A, Chikanishi T, et al. Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol 2009; 629: 118-124.
50. Shimizu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 1997; 63: S239-S243.
51. Ramachandra Rao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20: 1765-1775.
52. Salazar-Montes A, Ruiz-Corro L, Lopez-Reyes A, et al. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 2008; 595: 69-77.
53. Garcia L, Hernandez I, Sandoval A, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002; 37: 797-805.
54. Di Sario A, Bendia E, Macarri G, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha-I, TIMP-1 and MMP-2. Dig Liver Dis 2004; 36: 744-751.
55. Tada S, Nakamuta M, Enjoji M, et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol 2001; 28: 522-527.
56. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 173: 769-776.
57. Tamagawa K, Taooka Y, Maeda A, et al. Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2000; 161: 1279-1284.
58. Phan SH, Thrall RS, Williams C. Bleomycin-induced pulmonary fibrosis. Effects of steroid on lung collagen metabolism. Am Rev Respir Dis 1981; 124: 428-434.
59. Everett TH, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007; 4: S24-S27.
60. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFb, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010; 106: 1675-1680.
61. Ito Y, Aten J, Bende RJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998; 53: 853-861.
62. Cohen EP. Fibrosis causes progressive kidney failure. Med Hypotheses 1995; 45: 459-462.
63. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
64. Brook NR, Waller JR, Bicknell GR, et al. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model. Transplant Proc 2005; 37: 130-133.
65. Brook NR, Waller JR, Bicknell GR, et al. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. J Surg Res 2005; 125: 137-143.
66. Al-Bayati MA, Xie Y, Mohr FC, et al. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol 2002; 64: 517-525.
67. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250.
68. Kolb M, Xing Z, Gauldie J. Growth factors. In: Barnes P, Drazen J, Rennard S, et al., eds. Asthma and COPD. London, Academic Press, 2002; pp. 283-289.
69. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077-1091.
70. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114: 438-446.
71. Andersson-Sjoland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40: 2129-2140.
72. Lagente V, Boichot E, Pardo A, et al. Role of matrix metalloproteases in pulmonary fibrosis. In: Parnham MJ, ed. Matrix Metalloproteinases in Tissue Remodelling and Inflammation. Basle, Birkhäuser Basel, 2008; pp. 39-55.
73. Kelly M, Kolb M, Bonniaud P, et al. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003; 9: 39-49.
74. Liu RM, Gaston Pravia KA. Oxidative stress and glutathione in TGF-b-mediated fibrogenesis. Free Radic Biol Med 2010; 48: 1-15.
75. Bargagli E, Olivieri C, Bennett D, et al. Oxidative stress in the pathogenesis of diffuse lung diseases: a review. Respir Med 2009; 103: 1245-1256.
76. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15: 1077-1081.
77. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
78. Klingsberg RC, Mutsaers SE, Lasky JA. Current clinical trials for the treatment of idiopathic pulmonary fibrosis. Respirology 2010; 15: 19-31.
79. Di Sario A, Bendia E, Svegliati Baroni G, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 2002; 37: 584-591.
80. Ozes ON, Blatt LM. Development of a high throughput collagen assay using a cellular model of idiopathic pulmonary fibrosis. Chest 2006; 130: 230S.
81. Sulfab M, Blatt LM, Ozes ON. The effects of pirfenidone and interferon-inducible T-cell alpha chemoattractant on transforming growth factor-b1-mediated synthesis of extracellular matrix proteins in endothelial cells. Am J Respir Crit Care Med 2007; 175: A730.
82. Nakayama S, Mukae H, Sakamoto N, et al. Pirfenidone inhibits the expression of HSP47 in TGF-b1-stimulated human lung fibroblasts. Life Sci 2008; 82: 210-217.
83. Zhang S, Shiels IA, Ambler JS, et al. Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Aust NZ J Ophthalmol 1998; 26: S74-S76.
84. Hewitson TD, Kelynack KJ, Tait MG, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 2001; 14: 453-460.
85. Lin X, Yu M, Wu K, et al. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 2009; 50: 3763-3770.
86. Lee B-S, Margolin S, Nowak R. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metabol 1998; 83: 219-223.
87. Grattendick KJ, Nakashima JM, Feng L, et al. Effects of three anti- TNF-a drugs: etanercept, infliximab and pirfenidone on release of TNF-a in medium and TNF-a associated with the cell in vitro. Int Immunopharmacol 2008; 8: 679-687.
88. Phillips R, Wang T, Blatt LM, et al. Pirfenidone mediates differential effects on lipopolysaccharide-induced cytokine expression in human peripheral mononuclear cells. Chest 2005; 128: 169S.
89. Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-a at the translational level. Eur J Pharmacol 2002; 446: 177-185.
90. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-a, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002; 446: 167-176.
91. Mitani Y, Sato K, Muramoto Y, et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem Biophys Res Commun 2008; 372: 19-23.
92. Giri SN, Leonard S, Shi X, et al. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 1999; 18: 169-177.
93. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 2000; 204: 119-126.